Comparative Pharmacology
Head-to-head clinical analysis: EMVERM versus POVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMVERM versus POVAN.
EMVERM vs POVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.
None Documented
None Documented
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Terminal elimination half-life is approximately 16 hours; clinically, this supports single-dose administration with slow elimination
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Primarily fecal (90%) as unchanged drug via bile; renal excretion is minimal (<1%)
Category C
Category C
Anthelmintic
Anthelmintic